We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Read MoreHide Full Article
Key Takeaways
Allogene narrowed its Q2 loss to 13 cents per share, beating estimates on lower R&D spending.
The company's R&D costs fell 23.5%, while G&A expenses rose 45.9% and total operating costs declined.
Cash rose to $423.6 million, giving Allogene a runway into 2029 as cema-cel advances toward 2027 data.
Allogene Therapeutics (ALLO - Free Report) incurred a second-quarter 2026 loss of 13 cents per share, narrower than the Zacks Consensus Estimate of a loss of 16 cents. Lower research and development (R&D) spending supported the narrower loss. In the year-ago period, the company reported a loss of 23 cents.
Allogene recorded $4.6 million in collaboration revenues from related parties. It did not record any sales in the year-ago period.
ALLO Stock Performance
Shares of Allogene were up in after-market trading yesterday, likely due to the better-than-expected results.
Year to date, the stock has risen 51% compared with the industry’s nearly 6% growth.
Image Source: Zacks Investment Research
ALLO's R&D Costs Fall as G&A Spending Rises
R&D expenses were $30.7 million, down 23.5% year over year. In contrast, general and administrative (G&A) expenses rose 45.9% to $20.8 million.
Total operating expenses declined 9.3% to $51.6 million.
ALLO's Cash Position Extends Runway Into 2029
As of June 30, 2026, cash, cash equivalents and investments totaled $423.6 million compared with $266.9 million in the previous quarter. This uptick was due to the completion of a public offering in April that generated gross proceeds of $200.4 million. Based on its June-end liquidity, management expects a cash runway into 2029.
The company maintained operating expenses guidance for full-year 2026 at about $225 million, including non-cash stock-based compensation expense of nearly $35 million.
ALLO Progresses With Lead Pipeline Drug Development
Allogene’s main focus is the pivotal phase II ALPHA3 study, which evaluates the lead drug cema-cel as a potential first-line treatment for patients with newly diagnosed large B-cell lymphoma (LBCL) who are likely to relapse and require further therapy. In April, the company reported an interim futility analysis from the study, showing 58.3% MRD negativity at day 45 in patients treated with cema-cel versus 16.7% with observation. Management reported no treatment-related serious adverse events at the cutoff and said most patients were managed on an outpatient basis.
The company surpassed its 2026 goal of activating more than 80 ALPHA3 sites about six months early. It now expects approximately 100 sites to be active by year-end, with most in the United States and additional locations in Canada, Australia and South Korea. Despite faster site activation, Allogene still expects to provide an interim analysis on the primary endpoint of event-free survival (EFS) in mid-2027.
The ALPHA3 study is expected to randomize about 220 participants, with enrollment anticipated to be completed by year-end 2027.
Allogene Advances ALLO-329 Toward Q4 Readout
The company is also exploring the potential of allogeneic CAR T cell therapies in autoimmune diseases. It is enrolling patients in the phase I basket study (called RESOLUTION) evaluating ALLO-329 across autoimmune indications, including systemic lupus erythematosus, idiopathic inflammatory myopathies and systemic sclerosis.
With enrollment remaining brisk, Allogene expects a clinical and translational data update in the fourth quarter of 2026. Management said the readout should include at least the 20-million, 40-million and 80-million cell-dose cohorts, along with safety, efficacy and translational findings.
ALLO’s Zacks Rank
Allogene currently carries a Zacks Rank #3 (Hold).
Over the past 30 days, earnings per share (EPS) estimates for Anika Therapeutics have risen from 41 cents to $1.05 for 2026. Over the same period, EPS estimates have increased from 46 cents to 95 cents for 2027. ANIK shares have skyrocketed 129% year to date.
Anika Therapeutics missed on earnings in each of the trailing four quarters, delivering an average surprise of 950%.
Over the past 30 days, estimates for Repligen’s 2026 EPS have increased to $2.06 from $1.99. Over the same period, EPS estimates for 2027 have risen from $2.57 to $2.62. RGEN shares have gained 1% so far this year.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
View the Zacks #1 Rank List
Image: Bigstock
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Key Takeaways
Allogene Therapeutics (ALLO - Free Report) incurred a second-quarter 2026 loss of 13 cents per share, narrower than the Zacks Consensus Estimate of a loss of 16 cents. Lower research and development (R&D) spending supported the narrower loss. In the year-ago period, the company reported a loss of 23 cents.
Allogene recorded $4.6 million in collaboration revenues from related parties. It did not record any sales in the year-ago period.
ALLO Stock Performance
Shares of Allogene were up in after-market trading yesterday, likely due to the better-than-expected results.
Year to date, the stock has risen 51% compared with the industry’s nearly 6% growth.
Image Source: Zacks Investment Research
ALLO's R&D Costs Fall as G&A Spending Rises
R&D expenses were $30.7 million, down 23.5% year over year. In contrast, general and administrative (G&A) expenses rose 45.9% to $20.8 million.
Total operating expenses declined 9.3% to $51.6 million.
ALLO's Cash Position Extends Runway Into 2029
As of June 30, 2026, cash, cash equivalents and investments totaled $423.6 million compared with $266.9 million in the previous quarter. This uptick was due to the completion of a public offering in April that generated gross proceeds of $200.4 million. Based on its June-end liquidity, management expects a cash runway into 2029.
The company maintained operating expenses guidance for full-year 2026 at about $225 million, including non-cash stock-based compensation expense of nearly $35 million.
ALLO Progresses With Lead Pipeline Drug Development
Allogene’s main focus is the pivotal phase II ALPHA3 study, which evaluates the lead drug cema-cel as a potential first-line treatment for patients with newly diagnosed large B-cell lymphoma (LBCL) who are likely to relapse and require further therapy. In April, the company reported an interim futility analysis from the study, showing 58.3% MRD negativity at day 45 in patients treated with cema-cel versus 16.7% with observation. Management reported no treatment-related serious adverse events at the cutoff and said most patients were managed on an outpatient basis.
The company surpassed its 2026 goal of activating more than 80 ALPHA3 sites about six months early. It now expects approximately 100 sites to be active by year-end, with most in the United States and additional locations in Canada, Australia and South Korea. Despite faster site activation, Allogene still expects to provide an interim analysis on the primary endpoint of event-free survival (EFS) in mid-2027.
The ALPHA3 study is expected to randomize about 220 participants, with enrollment anticipated to be completed by year-end 2027.
Allogene Advances ALLO-329 Toward Q4 Readout
The company is also exploring the potential of allogeneic CAR T cell therapies in autoimmune diseases. It is enrolling patients in the phase I basket study (called RESOLUTION) evaluating ALLO-329 across autoimmune indications, including systemic lupus erythematosus, idiopathic inflammatory myopathies and systemic sclerosis.
With enrollment remaining brisk, Allogene expects a clinical and translational data update in the fourth quarter of 2026. Management said the readout should include at least the 20-million, 40-million and 80-million cell-dose cohorts, along with safety, efficacy and translational findings.
ALLO’s Zacks Rank
Allogene currently carries a Zacks Rank #3 (Hold).
Allogene Therapeutics, Inc. Price
Allogene Therapeutics, Inc. price | Allogene Therapeutics, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks in the biotech sector are Anika Therapeutics (ANIK - Free Report) and Repligen Corporation (RGEN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share (EPS) estimates for Anika Therapeutics have risen from 41 cents to $1.05 for 2026. Over the same period, EPS estimates have increased from 46 cents to 95 cents for 2027. ANIK shares have skyrocketed 129% year to date.
Anika Therapeutics missed on earnings in each of the trailing four quarters, delivering an average surprise of 950%.
Over the past 30 days, estimates for Repligen’s 2026 EPS have increased to $2.06 from $1.99. Over the same period, EPS estimates for 2027 have risen from $2.57 to $2.62. RGEN shares have gained 1% so far this year.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.